环氧合酶及其抑制剂与炎症性疾病关系的研究进展
作者：丘岳;杨斌;
Author：
收稿日期： 年卷（期）页码：2008,(04):-459-461
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：环氧合酶;炎症;环氧合酶抑制剂;非甾体抗炎药
Key words：
基金项目：广西自然科学基金(No:0575057)
中文摘要
环氧合酶是一种与炎症反应密切相关的诱导型合酶,可在多种刺激因子作用下激活表达,促进炎症反应的发生。文中重点从环氧合酶与各类炎症性疾病的关系以及非甾体抗炎药的研究进展方面进行综述。
参考文献
[1]邵建国,谢幸尔,姚建国,等.环氧合酶-2在慢性肝炎、肝硬化组织中的表达及临床意义[J].临床肝胆杂志,2006,22(6):422-424.
[2]崔俊峰,赵彩彦.环氧合酶在各种慢性肝病发病机制中的研究进展[J].河北医科大学学报,2007,28(4):308-311.
[3]王少鑫.环氧合酶-2对溃疡性结肠炎致病作用的研究进展[J].国外医学.消化系疾病分册,2002,22(3):151-153.
[4]Roberts P,Morgan K,Miller R,et al.Neuronal COX-2 expres-sion in human myenteric plexus in active inflammatory bowel dis-ease[J].Gut,2001,48(4):468-472.
[5]程艳梅,朱生梁,马淑颖,等.环氧合酶-2在反流性食管炎大鼠食管组织中表达的实验研究[J].胃肠病学,2005,10(4):208-211.
[6]张玲霞,张沥,陶梅.大鼠萎缩性胃炎中Bcl-2及cox-2蛋白表达[J].中国消化内镜,2007,1(1):34-37.
[7]Bolli R,Shinmuran K,Tang XL,et al.Descovery of a new func-tion of COX-2:COX-2 is cardioprotective protein that allevi-ates is-chemia/reperfusion[J].Cardiovaxcular Res,2002,55(3):506-519.
[8]Pitt B,Pepine C,Willerson JT.Cyclooxygenase-2 inhibition andcardiovascular events[J].Circulation,2002,106:167-169.
[9]甄琴,黄体钢.环氧合酶-2与动脉粥样硬化[J].实用心脑肺血管病杂志,2006,14(3):252-254.
[10]Swan SK,Rudy DW,Lasseter KC,et al.Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet.A randomized,controlled trial[J].Ann Int Medication,2000,133(1):1-9.
[11]Zoja C,Beningi A,Noris M,et al.Mycophenolate mofetil com-bined with a cyclooxygenase-2 inhibitor ameliprates murinelupus nephritis[J].Kidney International,2001,60(2):653-63.
[12]Anderson GD,Hauser SD,McGarity KL,et al.Selective inhibi-tion of cyclooxygenase COX-2 reverses inflammation and expres-sion of COX-2 and intreleukin 6 in rat adjuvant arthritis[J].Clinical Invest,1996,97(11):2672-2679.
[13]Tomasoni S,Noris M,Zappella S,et al.Upregulation of renal andsysremic cyclooxygenase-2 in patients with active lupus nephritis[J].BMC Nephrology,1998,9(7):1202-1212.
[14]李洁,王坚,赵明.炎症因子与糖尿病心肌病关系的实验研究[J].中华老年心脑血管病杂志,2006,8(7):478-480.
[15]董媛,张明昌.环氧合酶-2及其抑制剂对角膜新生血管作用的研究[J].眼科研究,2007,25(6):424-427.
[16]马燕,夏伦祝.COX-2抑制剂研究历程的回顾与思索[J].安徽医药,2007,11(3):249-250.
[17]大多数非选择性NSAID“与COX-2抑制剂一样有心脏病危险”[J].中国医药技术与市场,2007,7(4):60.
[18]Richard C,Becker MD.Keynote Address:COX-2 Inhibitors[J].Texas Heart Institute J,2005,32(3):380-383.
[19]Solomon SD,McMurray JJ,Pfeffer MA,et al.Cardiovascular riskassociated with celecoxib in a clinical trial for colorectal adenomaprevention[J].J Occupational Medicine and Toxicology(Lon-don,England),2005,35(2):1071-1080.
[20]刘武昆,周金培.非甾体抗炎药环氧化酶/5-脂氧化酶双重抑制剂的研究进展[J].药学进展,2007,31(2):64-67.
[21]Jonas J,Gopez MD,Hongfei Yue,et al.Cyclooxygenase-2-specific inhibitor improves functional outcomes,provides neuro-protection,and reduces inflammation in a rat model of traumaticbrain injury[J].Neurosurgery,2006,56(3):590-604.
【关闭】
